JP2002541111A - ウンデカン酸テストステロンとヒマシ油を含む調合物 - Google Patents
ウンデカン酸テストステロンとヒマシ油を含む調合物Info
- Publication number
- JP2002541111A JP2002541111A JP2000609075A JP2000609075A JP2002541111A JP 2002541111 A JP2002541111 A JP 2002541111A JP 2000609075 A JP2000609075 A JP 2000609075A JP 2000609075 A JP2000609075 A JP 2000609075A JP 2002541111 A JP2002541111 A JP 2002541111A
- Authority
- JP
- Japan
- Prior art keywords
- castor oil
- testosterone undecanoate
- liquid carrier
- weight
- dissolved
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- UDSFVOAUHKGBEK-CNQKSJKFSA-N testosterone undecanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCCCCCC)[C@@]1(C)CC2 UDSFVOAUHKGBEK-CNQKSJKFSA-N 0.000 title claims abstract description 32
- 229960000746 testosterone undecanoate Drugs 0.000 title claims abstract description 31
- 239000004359 castor oil Substances 0.000 title claims abstract description 24
- 235000019438 castor oil Nutrition 0.000 title claims abstract description 24
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 title claims abstract description 24
- 239000000203 mixture Substances 0.000 title claims abstract description 16
- 238000009472 formulation Methods 0.000 title abstract description 15
- 239000007788 liquid Substances 0.000 claims abstract description 24
- 239000004094 surface-active agent Substances 0.000 claims abstract description 11
- 239000002775 capsule Substances 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 3
- 239000003098 androgen Substances 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 2
- 229940100688 oral solution Drugs 0.000 claims description 2
- 230000009469 supplementation Effects 0.000 claims 1
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract description 16
- 229960003604 testosterone Drugs 0.000 abstract description 7
- ZITKDVFRMRXIJQ-UHFFFAOYSA-N dodecane-1,2-diol Chemical compound CCCCCCCCCCC(O)CO ZITKDVFRMRXIJQ-UHFFFAOYSA-N 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 229940030486 androgens Drugs 0.000 description 4
- 238000002657 hormone replacement therapy Methods 0.000 description 4
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 2
- 235000019961 diglycerides of fatty acid Nutrition 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 235000019960 monoglycerides of fatty acid Nutrition 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 description 1
- 206010002261 Androgen deficiency Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000009165 androgen replacement therapy Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229940026235 propylene glycol monolaurate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Fats And Perfumes (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99302581.6 | 1999-04-01 | ||
| EP99302581 | 1999-04-01 | ||
| PCT/EP2000/002677 WO2000059512A1 (en) | 1999-04-01 | 2000-03-27 | Formulation comprising testosteron undecanoate and castor oil |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002541111A true JP2002541111A (ja) | 2002-12-03 |
| JP2002541111A5 JP2002541111A5 (enExample) | 2007-04-05 |
Family
ID=8241306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000609075A Withdrawn JP2002541111A (ja) | 1999-04-01 | 2000-03-27 | ウンデカン酸テストステロンとヒマシ油を含む調合物 |
Country Status (26)
| Country | Link |
|---|---|
| EP (1) | EP1189620B1 (enExample) |
| JP (1) | JP2002541111A (enExample) |
| KR (1) | KR100666016B1 (enExample) |
| CN (1) | CN1155385C (enExample) |
| AT (1) | ATE269708T1 (enExample) |
| AU (1) | AU768537B2 (enExample) |
| BR (1) | BR0009465A (enExample) |
| CA (1) | CA2366856C (enExample) |
| CZ (1) | CZ298573B6 (enExample) |
| DE (1) | DE60011771T2 (enExample) |
| DK (1) | DK1189620T3 (enExample) |
| ES (1) | ES2222199T3 (enExample) |
| HU (1) | HU229455B1 (enExample) |
| ID (1) | ID30481A (enExample) |
| IL (2) | IL145524A0 (enExample) |
| MX (1) | MXPA01009919A (enExample) |
| NO (1) | NO329420B1 (enExample) |
| NZ (1) | NZ514290A (enExample) |
| PL (1) | PL195163B1 (enExample) |
| PT (1) | PT1189620E (enExample) |
| RU (1) | RU2246296C2 (enExample) |
| SK (1) | SK286071B6 (enExample) |
| TR (1) | TR200102769T2 (enExample) |
| TW (1) | TWI280124B (enExample) |
| WO (1) | WO2000059512A1 (enExample) |
| ZA (1) | ZA200107781B (enExample) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007530446A (ja) * | 2003-11-11 | 2007-11-01 | マッテルン，ウド | 鼻適用のための放出制御送達システム |
| US9186320B2 (en) | 2006-10-04 | 2015-11-17 | Mattern Pharma Ag | Controlled release delivery system for nasal application of neurotransmitters |
| US9757388B2 (en) | 2011-05-13 | 2017-09-12 | Acerus Pharmaceuticals Srl | Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels |
| US10111888B2 (en) | 2011-05-13 | 2018-10-30 | Acerus Biopharma Inc. | Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
| US10668084B2 (en) | 2011-05-13 | 2020-06-02 | Acerus Biopharma Inc. | Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
| JP2020090538A (ja) * | 2014-06-19 | 2020-06-11 | ソルラル ファーマ エーピーエス | 親油性の化合物の固体経口剤形 |
| US11090312B2 (en) | 2013-03-15 | 2021-08-17 | Acerus Biopharma Inc. | Methods of treating hypogonadism with transnasal testerosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9907715D0 (en) * | 1999-04-01 | 1999-05-26 | Scherer Corp R P | Pharmaceutical compositions |
| US6652880B1 (en) | 1999-04-01 | 2003-11-25 | R.P. Scherer Technologies, Inc. | Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants |
| JO2505B1 (en) | 2003-03-14 | 2009-10-05 | باير شيرنغ فارما اكتنجيسيلشافت | Pharmacy methods and formulations for obtaining acceptable serum testosterone levels |
| US8784869B2 (en) | 2003-11-11 | 2014-07-22 | Mattern Pharma Ag | Controlled release delivery system for nasal applications and methods of treatment |
| US20060140820A1 (en) | 2004-12-28 | 2006-06-29 | Udo Mattern | Use of a container of an inorganic additive containing plastic material |
| US8241664B2 (en) * | 2005-04-15 | 2012-08-14 | Clarus Therapeutics, Inc | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
| US8492369B2 (en) | 2010-04-12 | 2013-07-23 | Clarus Therapeutics Inc | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
| GB0818473D0 (en) | 2008-10-08 | 2008-11-12 | Probio Nutraceuticals As | Composition |
| US11304960B2 (en) * | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
| PH12012502016A1 (en) * | 2010-04-12 | 2013-01-21 | Clarus Therapeutics Inc | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
| GB201006200D0 (en) * | 2010-04-14 | 2010-06-02 | Ayanda As | Composition |
| US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
| US9119772B2 (en) * | 2011-01-26 | 2015-09-01 | Allergan, Inc. | Androgen composition for treating an opthalmic condition |
| EP3157505B1 (en) | 2014-06-17 | 2019-07-24 | Merck Sharp & Dohme B.V. | Stable formulations of testosterone undecanoate |
| WO2016033556A1 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS |
| US20170246187A1 (en) | 2014-08-28 | 2017-08-31 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
| RU2017111503A (ru) * | 2014-08-29 | 2018-10-05 | Липосин Инк. | КОМПОЗИЦИИ(17-β)-3-ОКСОАНДРОСТ-4-ЕН-17-ИЛ УНДЕКАНОАТА И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
| US20160361322A1 (en) | 2015-06-15 | 2016-12-15 | Lipocine Inc. | Composition and method for oral delivery of androgen prodrugs |
| US20180147215A1 (en) | 2016-11-28 | 2018-05-31 | Lipocine Inc. | Oral testosterone undecanoate therapy |
| AU2019308326B2 (en) * | 2018-07-20 | 2025-07-31 | Lipocine Inc. | Liver disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1102095A (zh) * | 1993-10-30 | 1995-05-03 | 浙江医科大学 | 长效雄激素类制剂——十一酸睾丸注射液 |
| GB9415810D0 (en) * | 1994-08-04 | 1994-09-28 | Jerrow Mohammad A Z | Composition |
| GB9608719D0 (en) * | 1996-04-26 | 1996-07-03 | Scherer Ltd R P | Pharmaceutical compositions |
| SE9700642D0 (sv) * | 1997-02-24 | 1997-02-24 | Kronvall Stefan Med Ab | Medel och sätt för förebyggande och behandling av det metabola syndromet |
-
2000
- 2000-03-27 WO PCT/EP2000/002677 patent/WO2000059512A1/en not_active Ceased
- 2000-03-27 TR TR2001/02769T patent/TR200102769T2/xx unknown
- 2000-03-27 CZ CZ20013507A patent/CZ298573B6/cs not_active IP Right Cessation
- 2000-03-27 CA CA002366856A patent/CA2366856C/en not_active Expired - Lifetime
- 2000-03-27 SK SK1372-2001A patent/SK286071B6/sk not_active IP Right Cessation
- 2000-03-27 EP EP00920588A patent/EP1189620B1/en not_active Expired - Lifetime
- 2000-03-27 DE DE60011771T patent/DE60011771T2/de not_active Expired - Lifetime
- 2000-03-27 DK DK00920588T patent/DK1189620T3/da active
- 2000-03-27 BR BR0009465-0A patent/BR0009465A/pt not_active Application Discontinuation
- 2000-03-27 JP JP2000609075A patent/JP2002541111A/ja not_active Withdrawn
- 2000-03-27 HU HU0200453A patent/HU229455B1/hu unknown
- 2000-03-27 IL IL14552400A patent/IL145524A0/xx active IP Right Grant
- 2000-03-27 CN CNB008059381A patent/CN1155385C/zh not_active Expired - Lifetime
- 2000-03-27 AU AU41111/00A patent/AU768537B2/en not_active Expired
- 2000-03-27 ID IDW00200102082A patent/ID30481A/id unknown
- 2000-03-27 MX MXPA01009919A patent/MXPA01009919A/es active IP Right Grant
- 2000-03-27 RU RU2001129362/15A patent/RU2246296C2/ru active
- 2000-03-27 AT AT00920588T patent/ATE269708T1/de active
- 2000-03-27 KR KR1020017012498A patent/KR100666016B1/ko not_active Expired - Lifetime
- 2000-03-27 PT PT00920588T patent/PT1189620E/pt unknown
- 2000-03-27 ES ES00920588T patent/ES2222199T3/es not_active Expired - Lifetime
- 2000-03-27 PL PL00351259A patent/PL195163B1/pl unknown
- 2000-03-27 NZ NZ514290A patent/NZ514290A/en not_active IP Right Cessation
- 2000-05-11 TW TW089109036A patent/TWI280124B/zh not_active IP Right Cessation
-
2001
- 2001-09-20 IL IL145524A patent/IL145524A/en not_active IP Right Cessation
- 2001-09-20 ZA ZA200107781A patent/ZA200107781B/en unknown
- 2001-09-28 NO NO20014718A patent/NO329420B1/no not_active IP Right Cessation
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007530446A (ja) * | 2003-11-11 | 2007-11-01 | マッテルン，ウド | 鼻適用のための放出制御送達システム |
| US9186320B2 (en) | 2006-10-04 | 2015-11-17 | Mattern Pharma Ag | Controlled release delivery system for nasal application of neurotransmitters |
| US9801834B2 (en) | 2006-10-04 | 2017-10-31 | M et P Pharma AG | Controlled release delivery system for nasal application of neurotransmitters |
| US9757388B2 (en) | 2011-05-13 | 2017-09-12 | Acerus Pharmaceuticals Srl | Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels |
| US10111888B2 (en) | 2011-05-13 | 2018-10-30 | Acerus Biopharma Inc. | Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
| US10668084B2 (en) | 2011-05-13 | 2020-06-02 | Acerus Biopharma Inc. | Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
| US11090312B2 (en) | 2013-03-15 | 2021-08-17 | Acerus Biopharma Inc. | Methods of treating hypogonadism with transnasal testerosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event |
| US11744838B2 (en) | 2013-03-15 | 2023-09-05 | Acerus Biopharma Inc. | Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event |
| JP2020090538A (ja) * | 2014-06-19 | 2020-06-11 | ソルラル ファーマ エーピーエス | 親油性の化合物の固体経口剤形 |
| JP7071420B2 (ja) | 2014-06-19 | 2022-05-18 | ソルラル ファーマ エーピーエス | 親油性の化合物の固体経口剤形 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002541111A (ja) | ウンデカン酸テストステロンとヒマシ油を含む調合物 | |
| JP2002541111A5 (enExample) | ||
| EP0904064B1 (en) | Oral pharmaceutical compositions containing sex hormones | |
| US20050287203A1 (en) | Formulation comprising testosteron undecanoate and castor oil | |
| KR101382725B1 (ko) | 소수성 약물의 약물전달시스템 및 이를 포함하는 조성물 | |
| JPH11512115A (ja) | 経口投与用製剤組成物 | |
| JPH0840880A (ja) | 軟ゼラチンカプセル剤中のケトプロフエン溶液に基づく医薬製剤およびその調製法 | |
| HK1043544B (en) | Formulation comprising testosteron undecanoate and castor oil | |
| JP2538816B2 (ja) | 動物用ビタミンａ製剤 | |
| JP2003510269A (ja) | バソプレシン拮抗薬製剤および方法 | |
| JP2002502878A (ja) | ベンゾキサジノンｈｉｖ逆転写酵素阻害剤の経口液体調合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070131 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070131 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20070416 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20090501 |